INTRODUCTION
============

Highly active antiretroviral therapy (HAART) is the current standard treatment for HIV infection but is associated with long term side effects. Nucleoside reverse transcriptase inhibitors (NRTI's), a major component of HAART, are associated with distal symmetrical polyneuropathy (DSP) \[[@R1]\]. This antiretroviral toxic neuropathy (ATN) occurs mainly but not exclusively with dideoxynucleotide analogue agents, e.g. stavudine and didanosine, and causes significant morbidity in 10-35% of patients \[[@R2],[@R3]\].

NRTI's interfere with mitochondrial metabolism by reducing neuronal mitochondrial DNA synthesis leading to a disruption of oxidative meta-bolism \[[@R1],[@R4]-[@R6]\]. Subsequently, peripheral axons die back as the neuronal mitochondria are unable to meet their metabolic requirements. Histological examination confirms reduced epidermal innervation in affected areas \[[@R7],[@R8]\].

Acetyl-L-carnitine (ALCAR) is an ester of L-carnitine and plays a major role in normal mitochondrial function, being a transport molecule for free fatty acids and an important acetyl-group donor in high-energy metabolism and free fatty acid beta-oxidation \[[@R9],[@R10]\]. Its main body stores are in skeletal and cardiac muscle. It is found along with free plasma L-carnitine and other acyl-esters of varying chain length \[[@R11]\]. The formation of ALCAR originates with cytoplasmic thiokinase which forms acyl-Coenzyme A from free fatty acids, ATP and Coenzyme A (CoA) \[[@R12]\]. This substance is combined with carnitine to form acetyl-carnitine *via*carnitine palmitoyltransferase I. Entry into the mitochondrial matrix occurs through an exchange system of acylcarnitine / carnitine *via*carnitine-acylcarnitine translocase. For each acylcarnitine molecule traversing the inner mitochondrial membrane, a molecule of carnitine is shuttles out. On the inner mitochondrial membrane, carnitine palmitoyltransferase II converts acylcarnitine to carnitine, liberating acylCoA. Finally, the production of ALCAR and CoA from carnitine and acetylCoA (obtained *via*beta-oxidation of acylCoA) occurs *via*carnitine acetyltransferase present in the mitochondrial matrix \[[@R12],[@R13]\]. The enzymatic formation of ALCAR in the mitochondrial matrix is reversible, releasing free Coenzyme A and acetylCoA which can readily be exchanged across membranes, thus providing metabolic energy to intracellular organelles.

ALCAR plasma levels are decreased in HIV positive patients suffering from ATN \[[@R14]\]. It appears that certain pathways of carnitine metabolism, such as the acetylation of carnitine to acetyl-carnitine, are impaired, possibly as a result of the toxicity of antiretroviral medication.

Oral treatment with ALCAR (1.5g twice daily) has shown some beneficial effect on symptoms and nerve regeneration in patients with ATN \[[@R15]-[@R18]\]. It is unknown whether the pharmacokinetic profile would allow a once daily administration.

METHODS
=======

The study was approved by the Royal Free Ethics Committee, London. Consent was obtained from all patients. The inclusion criteria for this cross over trial were: Male or female patients with confirmed HIV-1 infection (ELISA antibody testing), a stable antiretroviral combination that remained unchanged throughout the study, a clinical diagnosis of antiretroviral toxic neuropathy, and ALCAR therapy (1.5 g twice daily) for at least 3 months. Plasma samples for the measurement of ALCAR and L-carnitine levels were taken pre-dose (fasting) and 2-hour post-dose. Subsequently, the twice daily dose was changed to a range of once daily doses (1g, 2g, and 3g). Plasma sampling was repeated after 4 weeks.

Healthy volunteers, recruited from laboratory staff served as control. None of them was known to be HIV infected nor taking ALCAR.

Sensitive high pressure liquid chromatography (HPLC) with fluorometric detection as described elsewhere \[[@R19]\], was used for the measurement of ALCAR and L-carnitine in blood plasma. The procedure involves pre-column derivitisation with 1-aminoanthrecene performed in phosphate buffer in the presence of 1-(3-dimethylaminopropyl)-3-ethylcar-bodiimide hydrochloride as catalyst. The fluorescent derivatives were isocratically separated on a reversed-phase column. The eluate was monitored with fluorometric detector set at 248 nm (excitation wavelength) and 418 nm (emission wavelength). At the concentrations measured, the assay has been found to have an imprecision of less than 10%, as determined in preceding measurements. All plasma samples were processed and analysed in duplicate. A standard curve was plotted prior to each analytical run.

The data was normally distributed. A Student's t-test was used for analysis with statistical significance set at p\<0.05.

RESULTS
=======

Twenty-three HIV infected subjects on ALCAR therapy and 12 HIV uninfected control subjects were enrolled and completed the study. There were slightly more men in the treatment group and the control group was younger (Table **[1](#T1){ref-type="table"}**). Six patients in the treatment group were taking one NRTI, 13 were taking two NRTIs, 3 were taking 3 NRTIs in combination with 1-2 protease inhibitors (PI) and / or non-nucleoside reverse transcriptase inhibitors (NNRTI). One patient was taking an antiretroviral regime consisting of a PI and an NNRTI only. From 1.5 g ALCAR twice daily (23 patients, plasma levels from 15 patients obtained), the treatment was changed to once daily doses of 1g (4 patients), 2g (7 patients), or 3g (12 patients), respectively.

The plasma levels are shown in Table **[2](#T2){ref-type="table"}** and Figs. (**[1](#F1){ref-type="fig"}**) and (**[2](#F2){ref-type="fig"}**). When compared with the control group, all ALCAR plasma levels (pre and post dose) were significantly higher in the treatment groups (p \< 0.02). For L-carnitine, all post dose level were significantly higher than in the control group (p \< 0.03). Pre dose levels, however, were only significantly higher in the groups taking 1.5g twice daily (p = 0.03) or 2g once daily (p = 0.008). Accordingly, post dose levels were significantly higher than pre dose levels in patients taking 1g or 3g once daily (p \<0.05). There was no significant difference between any of the plasma levels (ALCAR and L-carnitine) in the treatment groups. In particular, there was no difference between once daily and twice daily regimen.

DISCUSSION
==========

As previously shown, plasma ALCAR levels are decreased in patients with ATN \[[@R14],[@R20]\]. Oral ALCAR supplementation seems to result in plasma levels that are higher than in healthy individuals. Our findings may therefore provide indirect support for reports that ALCAR promotes nerve fibre regeneration and can improve neuropathic symptoms \[[@R15]-[@R18]\].

No significant differences in plasma levels were seen in the different dosage groups despite a reduction of the total daily dose by up to two thirds (from 1.5g twice daily to 1g once daily). However, our study size was small and its results need to be interpreted with caution. The metabolism of ALCAR and L-carnitine is complex. It has been shown that peripheral blood monocytes in AIDS patients are low in intracellular L-carnitine \[[@R21]\]. Serum levels, however, may be high, low or normal and are therefore unreliable as an indicator of L-carnitine metabolism \[[@R22]\].

L-carnitine and ALCAR homeostasis are maintained by absorption from diet, a modest rate of synthesis, very efficient renal re-absorption and probably renal tubular secretion. Dietary ALCAR is hydrolysed partially during absorption in enterocytes, partially after absorption. Both ALCAR and L-carnitine plasma concentrations have been found to return to baseline within 12 hours after injection \[[@R23]\]. The key mechanism for this seems to be renal re-absorption that displays saturation kinetics. With rising L-carnitine concentrations, re-absorption decreases and clearance increases. This results in a rapid decline of circulating L-carnitine. Elimination kinetics for ALCAR are similar to those for L-carnitine \[[@R23]\].

Our data suggest that oral supplementation of ALCAR may increase the steady state concentration of ALCAR in blood plasma until its saturated renal kinetics prevent a further rise. However, continuous treatment with ALCAR may lead to mitochondrial storage which could explain why there is no significant difference between pre and post dose levels in most treatment groups. It may also explain why plasma levels remained elevated for more than 12 hours in contrast to reports on intravenous application \[[@R23]\].

However, it remains unknown whether high plasma levels are associated with high intra-mitochondrial levels. Given that the pathogenesis of antiretroviral toxic neuropathy is based on the disruption of mitochondrial energy supply one can assume that the clinical effect of ALCAR is dependent on its mitochondrial availability. There are, unfortunately, no readily available tests to evaluate mitochondrial toxicity of NRTIs nor intra-mitochondrial concentrations of ALCAR.

It appears that once daily and twice daily doses of ALCAR can achieve similar plasma levels. Therefore the easier administration schedule may be equally effective for the treatment of antiretroviral toxic neuropathy. Trials are needed to compare the clinical effect on symptoms and nerve regeneration.
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###### 

Baseline Characteristics (SD: Standard Deviation)

  -------------------------------------------- -------------------- ----------------------
                                               ALCAR Group (n=23)   Control Group (n=12)
  Men ;\#x0025;                                87                   75
  Mean age in years (range)                    43 (34 to 60)        35 (27 to 62)
  Time of HIV infection in years (SD)          10.5 (5.1)           NA
  Subjects with previous HIV related disease   7                    0
  Patients with \<50 cc/ml viral load          12                   12
  -------------------------------------------- -------------------- ----------------------

###### 

Mean Plasma Levels in µ5mol/l (Standard Deviation)

  ---------------- ------------------------ --------------------- --------------------- --------------------- --------------- ------------
                   1.5g ALCAR Twice Daily   1g ALCAR Once Daily   2g ALCAR Once Daily   3g ALCAR Once Daily   Control Group   
  (n=15\*)         (n=4)                    (n=7)                 (n=12)                (n=12)                                
  ALCAR            pre-dose                 7.6 (2.3)             7.1 (2.9)             7.7 (2.0)             7.1 (3.6)       4.3 (0.9)
  2hrs post-dose   7.7 (2.2)                6.8 (1.7)             6.8 (1.3)             7.5 (2.9)                             
  L-carnitine      pre-dose                 52.8 (18.3)           48.3 (8.1)            51.0 (8.2)            49.0 (15.5)     40.2 (7.0)
  2hrs post-dose   52.1 (17.9)              50.6 (7.5)            53.0 (5.0)            54.3 (16.9)                           
  ---------------- ------------------------ --------------------- --------------------- --------------------- --------------- ------------

^\*^ Values for 15 of 23 patients were obtained.
